Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

Abstract

Platinum-based chemotherapy appears to be effective in a high proportion of patients with BRCA1-associated breast cancers. Clinical trials are now warranted to determine the optimum treatment for this subgroup of breast cancer patients.